TriangleDISEASE & TREATMENT SETTING
SUTENT: Gastrointestinal stromal tumor after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Broader topic: Gastrointestinal Stromal Tumors
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after disease progression on or intolerance to imatinib mesylate
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for SUTENT (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice